Syra Health Reports 76% Net Loss Reduction in FY2025, Targets Profitability by Year-End 2026
SYRA has more than doubled off its 52-week low of $0.031.
Summary
Syra Health Corp. announced strong FY2025 financial results, including a 76% reduction in net loss and 157% growth in population health revenue, setting a target for profitability by year-end 2026.
Key Events · Earnings and Guidance · SYRA
-
Significant Net Loss Reduction
Full-year 2025 net loss improved by 76% to $896K, down from $3.8 million in FY2024.
-
Strong Population Health Revenue Growth
Population health revenue increased by 157% year-over-year to $5.3 million, driven by demand for higher-margin solutions.
-
Path to Profitability
The company expects to achieve profitability by year-end 2026, supported by disciplined cost management and new contract wins.
-
Improved Operational Efficiency
Operating expenses declined 37% to $3.4 million, and gross margin grew to 34.4% from 20.7% in FY2024.
Analysis · SYRA · Trade & Services
This 8-K officially releases Syra Health's full-year 2025 financial results, detailing significant operational improvements. The company dramatically reduced its net loss by 76% to $896K and saw population health revenue grow by 157%. With operating expenses down 37% and gross margins improving, management is now targeting profitability by year-end 2026. For a micro-cap company, this turnaround and clear path to profitability are critical for long-term viability and investor confidence, despite a slight overall revenue decrease due to specific federal funding changes.
At the time of this filing, SYRA was trading at $0.10 on OTC in the Trade & Services sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $0.03 to $0.41. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.